- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.03. | J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms | ||
| 12.03. | Argenx's Vyvgart tops Trinity's latest launch success analysis, beating out several Big Pharma debuts | ||
| 12.03. | AbbVie regained TV ad spending lead amid February slowdown, with Rinvoq and Skyrizi back on top | ||
| 12.03. | Johnson & Johnson CEO Joaquin Duato takes a 14% pay cut to $24.3M | ||
| 12.03. | Merck defeats claims it should have added safety warnings to Gardasil's label, knocking out 200+ lawsuits | ||
| 11.03. | A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3 | ||
| 11.03. | Merck opens $1B Gardasil manufacturing facility in North Carolina | ||
| 11.03. | As Humira succession plan played out, AbbVie's Rob Michael collected $18.5M in his first year as CEO | ||
| 11.03. | With AbbVie in its sights, Tenpoint names commercial chief ahead of vision drug launch | ||
| 11.03. | Knight Therapeutics stacks its Canadian armor with $99M Paladin buy | ||
| 11.03. | Viking pays $150M to recruit CordenPharma for obesity drug manufacturing saga | ||
| 11.03. | In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma | ||
| 10.03. | Indian contractor Syngene throws down $37M for Emergent's Baltimore biologics plant | ||
| 10.03. | By exercising long-held stock options, BioNTech CEO scored €260M payday in 2024 | ||
| 10.03. | Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment | ||
| 10.03. | Starboard CEO gets seat on Kenvue's board as activist investor, consumer health giant sign 'cooperation agreement' | ||
| 10.03. | Incyte's mixed Opzelura data in prurigo nodularis add uncertainty to potential approval bid: analysts | ||
| 10.03. | GSK, Novartis, Lilly among Big Pharmas celebrating International Women's Day 2025 | ||
| 10.03. | On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M | ||
| 10.03. | Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant Encelto | ||
| 10.03. | Novo Nordisk invites people with Type 2 diabetes into their 'Ozempic Eras' in star-studded campaign | ||
| 10.03. | With Eli Lilly flying high, CEO David Ricks collects 10% pay bump to $29.2M | ||
| 10.03. | Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis | ||
| 07.03. | Astellas, Yaskawa cement deal for robotic cell therapy production joint venture | ||
| 07.03. | Otsuka debuts new kid-friendly resources about Alzheimer's to ease burden on 'sandwich generation' caregivers |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
